NEW YORK, March 7 - Oxford GlycoSciences on Thursday said that CEO Michael Kranda will step down by the end of this year.

The company said Kranda, who has been at OGS for six years, cited "personal family reasons" for his decision to leave. Chairman G. Kirk Raab said the company has begun looking for a replacement.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.